Satoshi Oeda1,2, Hirokazu Takahashi3, Kento Imajo4, Yuya Seko5, Yuji Ogawa4, Michihisa Moriguchi5, Masato Yoneda4, Keizo Anzai3, Shinichi Aishima6, Masayoshi Kage7, Yoshito Itoh5, Atsushi Nakajima4, Yuichiro Eguchi8. 1. Liver Center, Saga University Hospital, 5-1-1 Nabeshima, Saga, 849-8501, Japan. 2. Department of Clinical Laboratory Medicine, Saga University Hospital, 5-1-1 Nabeshima, Saga, 849-8501, Japan. 3. Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan. 4. Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan. 5. Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyou-ku, Kyoto, 602-8566, Japan. 6. Department of Pathology & Microbiology, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan. 7. Center for Innovative Cancer Therapy, Kurume University Research, 67 Asahi-machi, Kurume, 830-0011, Japan. 8. Liver Center, Saga University Hospital, 5-1-1 Nabeshima, Saga, 849-8501, Japan. eguchiyu@cc.saga-u.ac.jp.
Abstract
BACKGROUND: Few studies have evaluated both liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease (NAFLD) using both FibroScan® M and XL probes. This study was performed to investigate the accuracy of both FibroScan® probes to diagnose liver fibrosis and steatosis in patients with NAFLD. METHODS: We prospectively enrolled 137 consecutive patients with clinically suspected NAFLD in our joint-research facilities. Liver biopsies, liver stiffness measurements (LSMs), and controlled attenuation parameter (CAP) measurements were performed, and 122 patients with NAFLD diagnosed pathologically by central pathologists were included in the final analysis. RESULTS: Reliable LSM results were obtained in 85.2% (M) and 89.3% (XL) of patients, and CAP was reliable in 90.2% (M) and 90.2% (XL). The median LSM was significantly lower with the XL than M probe, and CAP was significantly higher with the XL than M probe. The optimal cut-off values for diagnosing the fibrosis stage were lower for LSM with the XL than M probe (stage ≥ 2, 6.7 vs. 7.0; stage ≥ 3, 8.2 vs. 10.8; stage 4, 14.3 vs. 16.8, respectively), whereas those of CAP were higher for the XL than M probe (score of ≥ 2, 273 vs. 267; score of 3, 302 vs. 286, respectively). There were no significant differences in accuracy of the LSM and CAP between the probes. CONCLUSIONS: Liver fibrosis and steatosis could be equally evaluated with FibroScan® M and XL probes in patients with NAFLD. There was no significant difference in diagnostic accuracy between the two probes using probe-specific cut-off values.
BACKGROUND: Few studies have evaluated both liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease (NAFLD) using both FibroScan® M and XL probes. This study was performed to investigate the accuracy of both FibroScan® probes to diagnose liver fibrosis and steatosis in patients with NAFLD. METHODS: We prospectively enrolled 137 consecutive patients with clinically suspected NAFLD in our joint-research facilities. Liver biopsies, liver stiffness measurements (LSMs), and controlled attenuation parameter (CAP) measurements were performed, and 122 patients with NAFLD diagnosed pathologically by central pathologists were included in the final analysis. RESULTS: Reliable LSM results were obtained in 85.2% (M) and 89.3% (XL) of patients, and CAP was reliable in 90.2% (M) and 90.2% (XL). The median LSM was significantly lower with the XL than M probe, and CAP was significantly higher with the XL than M probe. The optimal cut-off values for diagnosing the fibrosis stage were lower for LSM with the XL than M probe (stage ≥ 2, 6.7 vs. 7.0; stage ≥ 3, 8.2 vs. 10.8; stage 4, 14.3 vs. 16.8, respectively), whereas those of CAP were higher for the XL than M probe (score of ≥ 2, 273 vs. 267; score of 3, 302 vs. 286, respectively). There were no significant differences in accuracy of the LSM and CAP between the probes. CONCLUSIONS:Liver fibrosis and steatosis could be equally evaluated with FibroScan® M and XL probes in patients with NAFLD. There was no significant difference in diagnostic accuracy between the two probes using probe-specific cut-off values.
Authors: Samer Gawrieh; Darly M Knoedler; Kia Saeian; James R Wallace; Richard A Komorowski Journal: Ann Diagn Pathol Date: 2010-11-24 Impact factor: 2.090
Authors: Gunda Millonig; Stefanie Friedrich; Stefanie Adolf; Hamidreza Fonouni; Mohammad Golriz; Arianeb Mehrabi; Peter Stiefel; Gudrun Pöschl; Markus W Büchler; Helmut Karl Seitz; Sebastian Mueller Journal: J Hepatol Date: 2009-12-04 Impact factor: 25.083
Authors: Sebastian Zenovia; Carol Stanciu; Catalin Sfarti; Ana-Maria Singeap; Camelia Cojocariu; Irina Girleanu; Mihaela Dimache; Stefan Chiriac; Cristina Maria Muzica; Robert Nastasa; Laura Huiban; Tudor Cuciureanu; Anca Trifan Journal: Diagnostics (Basel) Date: 2021-04-27
Authors: Alejandro Campos-Murguía; Astrid Ruiz-Margáin; José A González-Regueiro; Ricardo U Macías-Rodríguez Journal: World J Gastroenterol Date: 2020-10-21 Impact factor: 5.742
Authors: Kátia Cansanção; Marta Citelli; Nathalie Carvalho Leite; María-Carmen López de Las Hazas; Alberto Dávalos; Maria das Graças Tavares do Carmo; Wilza Arantes Ferreira Peres Journal: Nutrients Date: 2020-11-02 Impact factor: 5.717